Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Wave Life Sciences Ltd is a biotechnology business based in the US. Wave Life Sciences shares (WVE) are listed on the NASDAQ and all prices are listed in US Dollars. Wave Life Sciences employs 217 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.34|
|52-week range||$4.48 - $11.64|
|50-day moving average||$5.51|
|200-day moving average||$6.17|
|Wall St. target price||$9.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.08|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-15.73%|
|1 month (2021-09-24)||-29.77%|
|3 months (2021-07-23)||-25.68%|
|6 months (2021-04-23)||-28.50%|
|1 year (2020-10-23)||-45.68%|
|2 years (2019-10-23)||-80.23%|
|3 years (2018-10-23)||45.98|
|5 years (2016-10-21)||30.14|
|Revenue TTM||$15.7 million|
|Gross profit TTM||$-110,867,000|
|Return on assets TTM||-45.09%|
|Return on equity TTM||-864.74%|
|Market capitalisation||$261.5 million|
TTM: trailing 12 months
There are currently 1.3 million Wave Life Sciences shares held short by investors – that's known as Wave Life Sciences's "short interest". This figure is 30.8% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Wave Life Sciences shares can be evaluated.
Wave Life Sciences's "short interest ratio" (SIR) is the quantity of Wave Life Sciences shares currently shorted divided by the average quantity of Wave Life Sciences shares traded daily (recently around 488327.02702703). Wave Life Sciences's SIR currently stands at 2.59. In other words for every 100,000 Wave Life Sciences shares traded daily on the market, roughly 2590 shares are currently held short.
However Wave Life Sciences's short interest can also be evaluated against the total number of Wave Life Sciences shares, or, against the total number of tradable Wave Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Wave Life Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Wave Life Sciences shares in existence, roughly 20 shares are currently held short) or 0.0414% of the tradable shares (for every 100,000 tradable Wave Life Sciences shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Wave Life Sciences.
Find out more about how you can short Wave Life Sciences stock.
We're not expecting Wave Life Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Wave Life Sciences's shares have ranged in value from as little as $4.48 up to $11.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Wave Life Sciences's is 0.5529. This would suggest that Wave Life Sciences's shares are less volatile than average (for this exchange).
Wave Life Sciences Ltd. , a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc. , Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.